Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by SPCEO1on Oct 03, 2022 4:00pm
140 Views
Post# 35002411

RE:RE:RE:Trogarzo 30 sec i.v. push over two weeks

RE:RE:RE:Trogarzo 30 sec i.v. push over two weeksWith the last patient in the IM trial expected in November 2022, you are probably looking at at least a year before IM gets approved. But IM will not likely move the needle much for sales either asit is still an injection versus a pill, not to mention a small THTX sales force up against a much larger company in Viiv.

Trogarzo had a good chance to make hay before the competition arrived but failed to do so. I suspect these new methods of administration may be more intended to slow attrition of sales than to add meaningfully to them, but I hope I am wrong. 

Biobob wrote: How long will they market IV before IM gets the nod... I mean they do have to package and market IV version.... only to switch to IM like in a 2-3 years maybe....


<< Previous
Bullboard Posts
Next >>